Profile data is unavailable for this security.
About the company
Zhejiang Jiuzhou Pharmaceutical Co.,Ltd. is a China-based company principally engaged in the research, development, production and sales of chemical Active Pharmaceutical Ingredients (API) and intermediates. The Company mainly operates through two segments, including the New Drug and Intermediates Contract Development and Manufacturing Organization (CDMO) segment and the Specialty APIs and Intermediates segment. The New Drug and Intermediates CDMO segment mainly provides services for innovative medicines of pre-clinical chemical manufacturing and controls (CMC), clinical phases I, II and III, new drug application (NDA) and various stages after going public. The Specialty API and Intermediates segments mainly provides services including patent breakthroughs, production process improvement, drug certificate declaration, and cGMP standard commercial production for patented expired or soon-to-be-expired drugs for global chemical and generic drug manufacturers.
- Revenue in CNY (TTM)5.52bn
- Net income in CNY1.03bn
- Incorporated1998
- Employees4.88k
- LocationZhejiang Jiuzhou Pharmaceutical Co LtdNo.99, Waisha Road, Jiaojiang DistrictTAIZHOU 318000ChinaCHN
- Phone+86 57 688706789
- Fax+86 57 688706788
- Websitehttp://www.jiuzhoupharma.com
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Joinn Laboratories China Co Ltd | 2.38bn | 396.99m | 11.79bn | 2.50k | 32.18 | 1.53 | -- | 4.96 | 0.5299 | 0.5299 | 3.17 | 11.13 | 0.2331 | 0.6759 | 7.19 | -- | 3.84 | 8.99 | 4.59 | 11.07 | 42.29 | 46.76 | 16.48 | 32.01 | 3.58 | 6.97 | 0.0083 | 23.79 | 4.78 | 42.20 | -63.04 | 29.66 | 8.21 | 23.46 |
| Bio-Thera Solutions Ltd | 704.79m | -394.53m | 12.51bn | 1.17k | -- | 10.32 | -- | 17.75 | -0.9528 | -0.9528 | 1.70 | 2.93 | 0.3156 | 1.01 | 5.91 | 603,937.10 | -17.66 | -23.62 | -24.64 | -30.81 | 71.88 | 79.76 | -55.98 | -106.72 | 1.07 | -- | 0.2851 | -- | 54.86 | -- | 17.87 | -- | -3.78 | -- |
| Zhejiang CONBA Pharmaceutical Co., Ltd. | 6.73bn | 591.57m | 12.59bn | 8.41k | 21.44 | 1.79 | -- | 1.87 | 0.2286 | 0.2286 | 2.61 | 2.74 | 0.6074 | 2.34 | 6.53 | 800,475.20 | 6.09 | 6.77 | 8.71 | 10.50 | 57.22 | 63.24 | 10.02 | 11.10 | 1.40 | 23.14 | 0.1558 | 42.32 | 12.20 | -0.8267 | 65.20 | -6.21 | -11.64 | 5.92 |
| Henan Lingrui Pharmaceutical Co., Ltd. | 3.23bn | 526.17m | 13.06bn | 2.52k | 24.41 | 4.75 | -- | 4.04 | 0.9429 | 0.9429 | 5.83 | 4.85 | 0.7401 | 2.04 | 11.51 | 1,280,356.00 | 12.05 | 9.66 | 19.85 | 14.55 | 72.05 | 75.00 | 16.28 | 13.82 | 1.08 | -- | 0.0383 | 70.49 | 11.45 | 10.18 | 28.71 | 16.47 | -36.31 | 31.95 |
| Zhejiang Jiuzhou Pharmaceutical Co Ltd | 5.52bn | 1.03bn | 13.24bn | 4.88k | 12.66 | 1.56 | -- | 2.40 | 1.16 | 1.16 | 6.20 | 9.47 | 0.5887 | 1.75 | 6.76 | 1,132,544.00 | 10.99 | 10.10 | 13.99 | 13.69 | 36.77 | 34.64 | 18.67 | 16.26 | 2.63 | -- | 0.0754 | 40.79 | 1.44 | 24.29 | 12.20 | 45.74 | 32.14 | 20.11 |
| Sunshine Guojian Pharmcutcl Shngh Co Ltd | 1.01bn | 294.61m | 13.26bn | 965.00 | 45.01 | 2.71 | -- | 13.08 | 0.4777 | 0.4777 | 1.64 | 7.94 | 0.1949 | 1.11 | 7.36 | 1,050,813.00 | 5.45 | 1.32 | 5.82 | 1.41 | 76.98 | 80.74 | 27.94 | 6.55 | 6.67 | -- | 0.0102 | 8.25 | 22.84 | -2.35 | 497.63 | -4.44 | 21.22 | -- |
| Suzhou Zelgen Biopharmaceuticals Co Ltd | 386.57m | -260.85m | 13.47bn | 867.00 | -- | 8.45 | -- | 34.85 | -1.00 | -1.00 | 1.49 | 6.02 | 0.1621 | 0.2594 | 3.75 | 445,874.00 | -11.74 | -27.13 | -20.82 | -39.20 | 92.29 | 92.75 | -72.40 | -220.71 | 2.15 | -- | 0.3842 | -- | 27.83 | 211.81 | 39.08 | -- | 41.38 | -- |
| Mabwell Shanghai Bioscience Co Ltd | 127.84m | -1.05bn | 13.88bn | 1.49k | -- | 5.37 | -- | 108.56 | -2.64 | -2.64 | 0.3199 | 6.47 | 0.0282 | 0.0434 | 14.54 | 85,738.12 | -23.34 | -37.61 | -27.05 | -45.95 | 95.96 | 81.54 | -828.26 | -2,112.26 | 2.31 | -- | 0.3344 | -- | 361.03 | 27.88 | -10.28 | -- | 17.35 | -- |
| Shanghai Shyndec Pharmaceutical Co Ltd | 12.07bn | 691.88m | 13.95bn | 11.61k | 19.62 | 1.13 | -- | 1.16 | 0.530 | 0.530 | 9.24 | 9.24 | 0.6193 | 3.21 | 7.47 | 1,039,794.00 | 4.95 | 4.85 | 7.09 | 8.17 | 37.18 | 43.00 | 7.99 | 7.03 | 2.22 | -- | 0.1125 | 17.52 | -6.86 | 1.29 | 10.21 | -0.3897 | -2.21 | 0.00 |
| Holder | Shares | % Held |
|---|---|---|
| Zhong Ou Asset Management Co., Ltdas of 30 Sep 2023 | 63.81m | 7.68% |
| ICBC Credit Suisse Asset Management Co., Ltd.as of 30 Jun 2023 | 39.61m | 4.77% |
| China Universal Asset Management Co., Ltd.as of 30 Jun 2023 | 18.38m | 2.21% |
| GF Fund Management Co., Ltd.as of 30 Jun 2023 | 14.25m | 1.71% |
| Yinhua Fund Management Co., Ltd.as of 30 Jun 2023 | 14.10m | 1.70% |
| Hwabao WP Fund Management Co., Ltd.as of 30 Sep 2023 | 13.95m | 1.68% |
| Morgan Stanley Huaxin Fund Management Co., Ltd.as of 30 Jun 2023 | 12.33m | 1.48% |
| Huatai-PineBridge Fund Management Co., Ltd.as of 30 Jun 2023 | 9.22m | 1.11% |
| China Merchants Fund Management Co., Ltd.as of 30 Jun 2023 | 5.99m | 0.72% |
| Harvest Fund Management Co., Ltd.as of 30 Jun 2023 | 4.99m | 0.60% |
